Gossamer Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.5%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.40next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly99.2MTarget: Sufficient to fund operations into Q1 2027
Collaboration Revenue (Chiesi Partnership) Quarterly17MTarget: Ongoing cost-sharing and milestone-driven inflows
Net Loss Quarterly-46.7MTarget: Narrowing losses through cost containment and workforce reduction
Watch Items
- FDA Type B Pre-NDA Meeting OutcomeTrigger: FDA feedback on Phase 3 PROSERA data packageAction: Confirm regulatory path and alignment for NDA submission despite missing the primary endpoint's prespecified alpha
- NDA Submission for Seralutinib in PAHTrigger: Submission targeted for September 2026Action: Complete final clinical and pre-commercial preparations for filing
- Convertible Notes Exchange Offer SettlementTrigger: Reduction of outstanding 2027 convertible debt from $200M to $72MAction: Finalize execution of the exchange to extend debt maturity to 2030 and reduce near-term balance sheet pressure
- Workforce Restructuring and Cost ContainmentTrigger: 46% reduction in force (73 employees) initiated in March 2026Action: Monitor operating expense run-rate to ensure cash runway extends securely into Q1 2027
Research as of 19 Jun 2026